Ultragenyx Pharmaceutical
RARE
#3687
Rank
โ‚น312.16 B
Marketcap
โ‚น3,236
Share price
-0.83%
Change (1 day)
-22.34%
Change (1 year)

Earnings for Ultragenyx Pharmaceutical (RARE)

Earnings in 2025 (TTM): -โ‚น44.95 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current earnings are โ‚น0.63 Billion. In 2024 the company made an earning of -โ‚น45.35 Billion, an increase over its 2023 earnings that were of -โ‚น48.76 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Ultragenyx Pharmaceutical from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚น44.95 Billion-0.88%
2024 -โ‚น45.35 Billion-6.99%
2023 -โ‚น48.76 Billion-17.65%
2022 -โ‚น59.21 Billion55.52%
2021 -โ‚น38.07 Billion178.53%
2020 -โ‚น13.67 Billion-59.64%
2019 -โ‚น33.87 Billion1.46%
2018 -โ‚น33.38 Billion12.9%
2017 -โ‚น29.57 Billion32.63%
2016 -โ‚น22.3 Billion67.87%
2015 -โ‚น13.28 Billion160.2%
2014 -โ‚น5.11 Billion66.64%
2013 -โ‚น3.07 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
BioMarin Pharmaceutical
BMRN
โ‚น61.05 B-230.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
โ‚น0.44 B-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
-โ‚น2.47 Billion-94.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Lexicon Pharmaceuticals
LXRX
-โ‚น6.17 Billion-86.78%๐Ÿ‡บ๐Ÿ‡ธ USA